Bio-Rad Laboratories, Inc. (BIO.B)
NYSE: BIO.B · Real-Time Price · USD
259.17
+2.12 (0.82%)
Feb 17, 2026, 11:18 AM EST - Market open

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
1.02B1.04B
United States Revenue Growth
-1.80%-7.17%
EMEA Revenue
881.80M834.10M
EMEA Revenue Growth
5.72%1.74%
APAC Revenue
513.30M521.60M
APAC Revenue Growth
-1.59%-7.35%
Other Regional Revenue
165.40M169.30M
Other Regional Revenue Growth
-2.30%1.68%
Revenue (Total)
2.58B2.57B
Revenue (Total) Growth
0.65%-3.92%

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Life Science Revenue
1.02B1.03B
Life Science Revenue Growth
-0.68%-12.75%
Clinical Diagnostics Revenue
1.56B1.54B
Clinical Diagnostics Revenue Growth
1.57%3.26%
Other Segments Revenue
-500.00K
Other Segments Revenue Growth
--85.71%
Revenue (Total)
2.58B2.57B
Revenue (Total) Growth
0.65%-3.92%

Gross Profit

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Life Science Segment Profit
553.10M582.40M
Life Science Segment Profit Growth
-5.03%-12.29%
Clinical Diagnostics Segment Profit
786.80M796.60M
Clinical Diagnostics Segment Profit Growth
-1.23%4.33%
Other Segments Segment Profit
--100.00K
Gross Profit (Total)
1.34B1.38B
Gross Profit (Total) Growth
-2.83%-3.36%
Updated Dec 31, 2025. Data Source: Fiscal.ai.